FindTrial
Sign In

A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).

A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220215
Enrollment
Unknown
Registered
2006-03-06
Start date
2006-03-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHC with compensated LC

Interventions

investigational material(s) Generic name etc : Peginterferon alpha-2a and ribavirin INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administ

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and Female patients aged 20 to 75 years-old, diagnosed CHC with compensated LC, elevated ALT and detectable HCV RNA.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026